

of the drill site and board mats will be laid as a foundation for drilling operations within the leveed drill site area. The well will be drilled with a closed mud loop system and drilling residue will be hauled off for disposal.

Type of Application: U.S. Army Corps of Engineers (USACE) permit application # SWG-2019-00208. This application will be reviewed pursuant to Section 10 of the Rivers and Harbors Act of 1899 and Section 404 of the Clean Water Act.

CMP Project No: 19-1272-F1

Further information on the applications listed above, including a copy of the consistency certifications or consistency determinations for inspection, may be obtained from Ms. Allison Buchtien, P.O. Box 12873, Austin, Texas 78711-2873, or via email at federal.consistency@glc.texas.gov. Comments should be sent to Ms. Buchtien at the above address or by email.

TRD-201901355

Mark A. Havens

Chief Clerk and Deputy Land Commissioner

General Land Office

Filed: May 8, 2019

Department of State Health Services

Order Maintaining butyryl fentanyl and U-47700 in Schedule I; Placing furanyl fentanyl, 4-fluoroisobutyryl fentanyl, acryl fentanyl, tetrahydrofuranyl fentanyl, and ocfeentanil into Schedule I; and placing MAB-CHMINACA into Schedule I

The Administrator of the Drug Enforcement Administration issued a final order to permanently maintain the substances butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) and U-47700

(3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, into schedule I of the Controlled Substances Act, effective April 20, 2018. This final order was published in the *Federal Register*, Volume 83, Number 77, pages 17486-17488.

This scheduling action was taken pursuant to the following:

1. The 61st session of the Commission on Narcotic drugs, added butyryl fentanyl and U-47700 to schedule I of the Single Convention on Narcotic Drugs (1961);
2. The United States is obligated to similarly control butyryl fentanyl and U-47700 to schedule I as required by the Single Convention on Narcotic Drugs (1961); and
3. Butyryl fentanyl and U-47700 have no currently accepted medical use in treatment in the United States.

The Acting Administrator of the Drug Enforcement Administration issued a final order to permanently maintain the placement of the substances furanyl fentanyl [*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylfuran-2-carboxamide]; 4-fluoroisobutyryl fentanyl [*N*-(4-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide] (Other name: *para*-fluoroisobutyryl fentanyl); acryl fentanyl [*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacrylamide] (Other name: acryloylfentanyl); tetrahydrofuranyl fentanyl [*N*-(1-phenethylpiperidin-4-yl)-*N*-phenyltetrahydrofuran-2-carboxamide], and ocfeentanil [*N*-(2-fluorophenyl)-2-methoxy-*N*-(1-phenethylpiperidin-4-yl)acetamide], including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances

Act effective November 29, 2018. This final order was published in the *Federal Register*, Volume 83, Number 230, pages 61320-61323.

This scheduling action was taken pursuant to the following:

1. The 61st session of the Commission on Narcotic drugs, added furanyl fentanyl, 4-fluoroisobutyryl fentanyl, acryl fentanyl, tetrahydrofuranyl fentanyl, and ocfeentanil to schedule I of the Single Convention on Narcotic Drugs (1961);
2. The United States is obligated to similarly control furanyl fentanyl, 4-fluoroisobutyryl fentanyl, acryl fentanyl, tetrahydrofuranyl fentanyl, and ocfeentanil to schedule I as required by the Single Convention on Narcotic Drugs (1961); and
3. Furanyl fentanyl, 4-fluoroisobutyryl fentanyl, acryl fentanyl, tetrahydrofuranyl fentanyl, and ocfeentanil have no currently accepted medical use in treatment in the United States.

The Drug Enforcement Administration issued a final rule placing *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (Other names: MAB-CHMINACA; ADB-CHMINACA), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act effective January 29, 2019. This final rule was published in the *Federal Register*, Volume 84, Number 19, pages 444-448.

This scheduling action was taken pursuant to the following:

1. MAB-CHMINACA has a high potential for abuse that is comparable to other schedule I substances such as delta-9-tetrahydrocannabinol and JWH-018;
2. MAB-CHMINACA has no currently accepted medical use in treatment in the United States; and
3. There is a lack of accepted safety for use of MAB-CHMINACA under medical supervision.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the *Federal Register*. In the capacity as Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substances furanyl fentanyl, 4-fluoroisobutyryl fentanyl, acryl fentanyl, tetrahydrofuranyl fentanyl, ocfeentanil, butyryl, U-47700, and MAB-CHMINACA be permanently placed into schedule I.

These amendments shall be reflected in the 2019 annual republication of the schedules of controlled substances.

TRD-201901368

Barbara L. Klein

General Counsel

Department of State Health Services

Filed: May 8, 2019

Schedules of Controlled Substances

PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS.

This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of